# US 2010/0129868 A1 · Delta 4,5 glycuronidase compositions and methods related thereto

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0129868 A1
- Document ID: US20100129868A1
- Status: Published application
- Kind: A1
- Application number: 12/616,764
- Filed: 2009-11-11
- Published: 2010-05-27
- Earliest claimed: 2002-05-03
- Assignees: Massachusetts Institute of Technology
- Inventors: James R. Myette; Zachary Shriver; Ganesh Venkataraman; Ram Sasisekharan; Maitland W. McLean
- Web page: https://patentgrep.com/patent/US20100129868A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12Q 1/34: involving hydrolase
- C12Y 302/01056: Glucuronosyl-disulfoglucosamine glucuronidase (3.2.1.56), i.e. glycuronidase
- C12Y 302/01166: Heparanase (3.2.1.166)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to Δ4,5 glycuronidase, related compositions, and methods of use thereof.

## Claims

### Claim at position 1

-49. (canceled)

### Claim 50

A method for the recombinant production of substantially pure Δ4, 5 glycuronidase, comprising: a) introducing into a host cell a nucleic acid encoding Δ4, 5 glycuronidase or a variant thereof; b) expressing recombinant Δ4, 5 glycuronidase in the host cell; and c) isolating the recombinant Δ4, 5 glycuronidase from the host cell to produce substantially pure Δ4, 5 glycuronidase.

### Claim 51 (depends on 50)

The method of claim 50, wherein the nucleic acid encoding .4, 5 glycuronidase comprises SEQ ID NO:2 or a variant thereof.

### Claim 52 (depends on 50)

The method of claim 50, wherein the nucleic acid encoding M, 5 glycuronidase comprises SEQ ID NO:4 or a variant thereof.

### Claim 53 (depends on 50)

The method of claim 50, wherein the nucleic acid encodes Δ4, 5 glycuronidase having the amino acid sequences of SEQ ID NO: 1 or a functional variant thereof.

### Claim 54 (depends on 50)

The method of claim 50, wherein the nucleic acid encodes Δ4, 5 glycuronidase having the amino acid sequences of SEQ ID NO: 3 or a functional variant thereof.

### Claim 55 (depends on 50)

The method of claim 50, wherein the nucleic acid is operably linked to a promoter.

### Claim 56 (depends on 55)

The method of claim 55, wherein an expression vector comprises the nucleic acid that is operably linked to a promoter.

### Claim 57 (depends on 56)

The method of claim 56, wherein the expression vector is a prokaryotic or eukaryotic expression system.

### Claim 58 (depends on 50)

The method of claim 50, wherein the substantially pure Δ4, 5 glycuronidase is greater than about 91% free of contaminants.

### Claim 59 (depends on 50)

The method of claim 50, wherein the substantially pure Δ4, 5 glycuronidase is greater than about 95% free of contaminants.

### Claim 60 (depends on 50)

The method of claim 50, wherein the substantially pure Δ4, 5 glycuronidase is greater than about 99% free of contaminants.

### Claim 61 (depends on 50)

The method of claim 50, wherein the recombinant Δ4, 5 glycuronidase is isolated using chromatography or electrophoresis.

### Claim 62 (depends on 51)

The method of claim 51, wherein the nucleic acid variant encodes a recombinant Δ4, 5 glycuronidase having the amino acid sequences of SEQ ID NO:1 and differs from the nucleic acid comprising SEQ ID NO:2 due to the degeneracy of the genetic code.

### Claim 63 (depends on 52)

The method of claim 52, wherein the nucleic acid variant encodes a recombinant Δ4, 5 glycuronidase having the amino acid sequences of SEQ ID NO:3 and differs from the nucleic acid comprising SEQ ID NO:4 due to the degeneracy of the genetic code.

### Claim 64 (depends on 50)

The method of claim 50, wherein the nucleic acid variant encodes a recombinant Δ4, 5 glycuronidase comprising one or more modifications to the primary amino acid sequence of a naturally occurring Δ4, 5 glycuronidase polypeptide.

### Claim 65 (depends on 64)

The method of claim 64, wherein the modification is a conservative amino acid substitution.

### Claim 66 (depends on 64)

The method of claim 64, wherein the modifications to the primary amino acid sequence of a naturally occurring Δ4, 5 glycuronidase polypeptide results in enhanced protein stability in an expression system or enhanced stability of protein-protein binding.

### Claim 67 (depends on 50)

The method of claim 50, wherein the substantially pure Δ4, 5 glycuronidase further comprises a detectable moiety, a linker molecule, a fatty acid, or a fusion protein.

### Claim 68 (depends on 50)

The method of claim 50, wherein the host cell is selected from the group consisting of: yeast, fungi, insect cells, mammalian cells, E. coli, Flavobacterium heparinum, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia.

### Claim 69 (depends on 56)

The method of claim 56, wherein the expression vector is selected from the group consisting of: pBR322, pUC18, pUC19, ColE1, pSC101, pACYC 184, πVX, pC194, pC221, pT127, λgt10, λgt11, BPV, EBV, SV40, 2-micron circle, pMAM-neo, and pKRC.

### Claim 70 (depends on 55)

The method of claim 55, wherein the promoter is selected from the group consisting of: int promoter; bla promoter; CAT promoter; bacteriophage 2 (PL and PR) promoter; E. coli promoter trp, recA, lacZ, lad, gal; α-amylase promoter; B. subtilis ζ-28-specific promoter, actin promoter, collagen promoter, myosin promoter, mouse metallothionein I gene promoter; TK promoter of Herpes virus; SV40 early promoter; and yeast gal4 gene sequence promoter.

### Claim 71 (depends on 67)

The method of claim 67, wherein the detectable moiety is a 6× His tag and the host cell is a bacterial cell

### Claim 72 (depends on 71)

The method of claim 71, wherein the method comprises harvesting and lysing the bacterial cell to obtain a crude lysate; fractionating and filtering the crude lysate; purifying the recombinant Δ4, 5 glycuronidase by metal chelation chromatography; and cleaving the 6× His tag with thrombin.
